Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Mallinckrodt
McKesson
Dow
Moodys

Last Updated: September 25, 2022

DRIZALMA SPRINKLE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Drizalma Sprinkle, and when can generic versions of Drizalma Sprinkle launch?

Drizalma Sprinkle is a drug marketed by Sun Pharm and is included in one NDA. There are four patents protecting this drug.

This drug has one patent family member in one country.

The generic ingredient in DRIZALMA SPRINKLE is duloxetine hydrochloride. There are forty-two drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the duloxetine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Drizalma Sprinkle

A generic version of DRIZALMA SPRINKLE was approved as duloxetine hydrochloride by AUROBINDO PHARMA LTD on December 11th, 2013.

  Try it Free

Summary for DRIZALMA SPRINKLE
International Patents:1
US Patents:4
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in DRIZALMA SPRINKLE?DRIZALMA SPRINKLE excipients list
DailyMed Link:DRIZALMA SPRINKLE at DailyMed
Drug patent expirations by year for DRIZALMA SPRINKLE
Anatomical Therapeutic Chemical (ATC) Classes for DRIZALMA SPRINKLE

US Patents and Regulatory Information for DRIZALMA SPRINKLE

DRIZALMA SPRINKLE is protected by four US patents.

Patents protecting DRIZALMA SPRINKLE

Duloxetine sprinkles
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Duloxetine sprinkles
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Duloxetine sprinkles
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Duloxetine sprinkles
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm DRIZALMA SPRINKLE duloxetine hydrochloride CAPSULE, DELAYED REL PELLETS;ORAL 212516-001 Jul 19, 2019 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Sun Pharm DRIZALMA SPRINKLE duloxetine hydrochloride CAPSULE, DELAYED REL PELLETS;ORAL 212516-002 Jul 19, 2019 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Sun Pharm DRIZALMA SPRINKLE duloxetine hydrochloride CAPSULE, DELAYED REL PELLETS;ORAL 212516-001 Jul 19, 2019 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Sun Pharm DRIZALMA SPRINKLE duloxetine hydrochloride CAPSULE, DELAYED REL PELLETS;ORAL 212516-003 Jul 19, 2019 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Sun Pharm DRIZALMA SPRINKLE duloxetine hydrochloride CAPSULE, DELAYED REL PELLETS;ORAL 212516-002 Jul 19, 2019 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Sun Pharm DRIZALMA SPRINKLE duloxetine hydrochloride CAPSULE, DELAYED REL PELLETS;ORAL 212516-004 Jul 19, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for DRIZALMA SPRINKLE

See the table below for patents covering DRIZALMA SPRINKLE around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 3335697 ÉCLATS DE DULOXÉTINE (DULOXETINE SPRINKLES) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for DRIZALMA SPRINKLE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0273658 2005C/001 Belgium See Plans and Pricing PRODUCT NAME: CHLORHYDRATE DE DULOXETINE; REGISTRATION NO/DATE: EU/1/04/280/001 20040811
0273658 SPC/GB05/003 United Kingdom See Plans and Pricing PRODUCT NAME: DULOXETINE AND PHARMACUETICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, AND IN PARTICULAR DULOXETINE HYDROCHLORIDE; REGISTERED: UK EU/1/04/280/001 20040811; UK EU/1/04/280/002 20040811; UK EU/1/04/280/003 20040811; UK EU/1/04/280/004 20040811; UK EU/1/04/280/005 20040811; UK EU/1/04/280/006 20040811
0273658 C300171 Netherlands See Plans and Pricing PRODUCT NAME: DULOXETINE EN FARMACEUTISCH AANVAARDBARE ZUURADDITIEZOUTEN DAARVAN, EN IN HET BIJZONDER DULOXETINE HYDROCHLORIDE; NATL REGISTRATION NO/DATE: EU/1/04/280/001-006 20040811
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Baxter
Merck
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.